Mark D. Plinio - 14 Jun 2021 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
Chief Commercial Officer
Signature
/s/ Daniel S. Char, Attorney-in-Fact for Mark D. Plinio
Issuer symbol
EVLO on OTC
Transactions as of
14 Jun 2021
Net transactions value
$0
Form type
4
Filing time
16 Jun 2021, 16:18:10 UTC
Next filing
21 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +250,000 $0.000000 250,000 14 Jun 2021 Common Stock 250,000 $16.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of underlying shares will vest on 1st anniversary of employment commencement date (i.e., June 14, 2022), and remaining 75% of underlying shares will vest in 36 substantially equal monthly installments thereafter